You can access the full publication in Frontiers here.
The Rosell® Institute for Microbiome and Probiotics, in collaboration with Nimble Science, is pleased to announce the publication of the manuscript titled “Spatially and Temporally Precise Microbiome Profiling in the Small Intestine Using the SIMBA™ Capsule with X-Ray Tracking” in Frontiers of Microbiome.
This groundbreaking clinical study validates the in vivo use of the SIMBA capsule for capturing small intestine (SI) microbiome samples before and after intervention. The results demonstrate the efficacy of Nimble’s novel passive sampling method, known as the Small Intestine MicroBiome Aspiration (SIMBA™) capsule, in real-time collection of probiotic ingestions from the small intestine.
Nimble Science CEO Sabina Bruehlmann stated: “High-quality direct sampling of the small intestine has the potential to transform how microbiome-based therapies are identified, developed, and launched. Collaborating on the validation of the SIMBA capsule with industry leaders, such as the Rosell® Institute for Microbiome and Probiotics by Lallemand, has ensured the device is ready to answer the industry’s most pressing scientific questions.”
The SIMBA™ capsule, developed and commercialized by Nimble Science, offers the first convenient, high-quality, and reliable method for studying the microenvironment of the SI. Its spatially and temporally precise multi-omic bioinformation about the small intestine opens new avenues for multiple research frontiers, including probiotics and host-microbiota interactions, nutrients absorption and disease mechanisms.
In a follow-up clinical study by Nimble Science, currently under review for publication, the study shows that samples collected with the SIMBA™ capsule are comparable to those obtained through traditional endoscopy and are suitable for multi-omics analyses.
Sylvie Binda, Vice President of Research and Development at Lallemand Health Solutions, emphasized: “Our collaboration with Nimble Science continues, and we are eager to begin a new clinical trial on participants with small intestinal bacterial overgrowth (SIBO).”
You can access the full publication in Frontiers here.
Nimble Science is a health technology company that delivers precision GI insights to create a paradigm shift in GI product innovation across nutritional, diagnostic, and treatment capabilities, delivering the opportunity for truly personalized healthcare solutions. Fulfilling a critical void, Nimble’s GI Analytics Platform leverages a passive ingestible capsule to deliver accurate data directly from the small intestine with a simple home-use kit.
At the Rosell® Institute for Microbiome and Probiotics by Lallemand, our mission is to apply leading-edge technologies and innovative scientific approaches to improve human health. We achieve this by understanding the interaction between people and their functional microbiome. The Rosell® Institute operates as one of the research centers within Lallemand Health Solutions, a global leader in the probiotic industry, specializing in bacteria- and yeast-based probiotic supplements for human health, food applications, and nutricosmetics.
For media inquiries, please contact:
Sabina Bruehlmann, CEO Nimble Science sabina@nimblesci.com
Marilou Luneau, Communications Manager, Lallemand Health Solutions mluneau@lallemand.com
Comments